Phase I study of an antisense oligonucleotide to protein kinase C-α (ISIS 3521/CGP 64128A) in patients with cancer

Clinical Cancer Research

Volumn 5, Issue 11, 1999, Pages 3357-3363

  Yuen, Alan R ^a,c   Halsey, Joanne ^a   Fisher, George A ^a   Holmlund, Jon T ^b   Geary, Richard S ^b   Kwoh, T Jesse ^b   Dorr, Andrew ^b   Sikic, Branimir I ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ISIS PHARMACEUTICALS   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ISIS 3521; MESSENGER RNA; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PROTEIN KINASE C;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; DRUG URINE LEVEL; FATIGUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MALIGNANT NEOPLASTIC DISEASE; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTOPENIA; TUMOR GROWTH;

ADULT; AGED; AREA UNDER CURVE; BASE SEQUENCE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PROTEIN KINASE C; PROTEIN KINASE C-ALPHA; SENSITIVITY AND SPECIFICITY; THIONUCLEOTIDES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0032730633     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Orr, R., and Monia, B. Antisense therapy for cancer. Curr. Res. Mol. Therapeutics, 1: 102-108, 1998.
2. Bishop, M. R., Iversen, P. L., Bayever, E., Sharp, J. G., Greiner, T. C., Copple, B. L., Ruddon, R., Zon, G., Spinolo, J., Arneson, M., Armitage, J. O., and Kessinger, A. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J. Clin. Oncol., 14: 1320-1326, 1996.
3. Webb, A., Cunningham, D., Cotter, F., Clarke, P. A., di Stefano, F., Ross, P., Corbo, M., and Dziewanowska, Z. BCL-2 anti-sense therapy in patients with non-Hodgkin lymphoma. Lancet, 349: 1137-1141, 1997.
4. Nishizuka, Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature (Lond.), 334: 661-665, 1988.
5. O'Brian, C., Vogel, V. G., Singletary, S. E., and Ward, N. E. Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res., 49: 3215-3217, 1989.
6. Morotomi, M., Guillem, J. G., LoGerfo, P., and Weinstein, I. B. Production of diacylglycerol, an activator of protein kinase C, by human intestinal microflora. Cancer Res., 50: 3595-3599, 1990.
7. Kopp, R., Noelke, B., Sauter, G., Schildberg, F. W., Paumgartner, G., and Pfeiffer, A. Altered protein kinase C activity in biopsies of human colonic adenomas and carcinomas. Cancer Res., 51: 205-210, 1991.
8. Ha genes are mediated by protein kinase C-α. Cancer Res., 54: 6413-6420, 1994.
9. Ways, D. K., Kukoly, C. A., deVente, J., Hooker, J. L., Bryant, W. O., Posekany, K. J., Fletcher, D. J., Cook, P. P., and Parker, P. J. MCF-7 breast cancer cells transfected with protein kinase C-α exhibit altered expression of other protein kinase C isotbrms and display a more aggressive neoplastic phenotype. J Clin Invest., 95: 1906-1915, 1995.
10. Basu, A. The potential of protein kinase C as a target for anticancer treatment. Pharrnacol. Ther., 59: 257-280, 1993.
11. Dean, N. M., McKay, R., Condon, T. P., and Bennett, C. F. Inhibition of protein kinase C-α expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J. Biol. Chem., 269: 16416-16424, 1994.
12. Yazaki, T., Ahmad, S., Chahlavi, A., Zylber-Katz, E., Dean, N. M., Rabkin, S. D., Martuza, R. L., and Glazer, R. I. Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-α phosphorothioate oligodeoxynucleotide. Mol. Pharmacol., 50: 236-242, 1996.
13. Henry, S., Monteith, D., and Levin, A. Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicologic properties of phosphorothioate oligonucleotides. Anticancer Drug Design, 12: 395-408, 1997.
14. Wyrzykiewicz, T., and Cole, D. Stereo-reproducibility of the phosphoramidite method in the synthesis of oligonucleotide phosphorothioates. Bioorganic Chem., 23: 33-41, 1995.
15. Leeds, J. M., Graham, J. M., Truong, L., and Cummins, L. L. Quantitation of phosphorothioate oligonucleotides in human plasma. Anal. Biochem., 235: 36-43, 1996.
16. Geary, R. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligonucleotides. Anticancer Drug Design, 12: 383-393, 1997.
17. Holmlund, J., Nemunaitis, J., Schiller, J., Dorr, A., and Kisner, D. Phase I trial of c-raf antisense oligonucleotide ISIS 5132 (CGP69846A) by 21-day continuous intravenous infusion (CIV) in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol., 17: 210, 1998.
18. Propper, D., McDonald, A., Thavasu, P., Balkwill, F., Caponigro, F., Yap, A., Champain, K., Csermak, K., Talbot, D., Kaye, S., Harris, A., and Twelves, C. Phase I study of the protein kinase C inhibitor CGP 41251: tolerability and effects on signal transduction ex-vivo. Proc. 10th NCI-EORTC Symp. New Drugs Cancer Ther., 10: 112, 1998.
19. Senderowicz, A., Headlee, D., Lush, R., Arbuck, S., Bauer, K., Figg, W., Murgo, A., Inoue, K., Kobashi, S., Kuwabara, T., and Sausville, E. Phase I trial of infusional UCN-01, a novel protein kinase inhibitor, in patients with refractory neoplasms. Proc. 10th NCI-EORTC Symposium New Drugs Cancer Ther., 10: 111, 1998.
20. Nemunaitis, J., Von Hoff, D., Holmlund, J., Dorr, A., and Eckhardt, S. Phase I/pharmacokinetic (PK) trial of a protein kinase C-a antisense oligonucleotide, ISIS 3521 (CGP 64128A), administered thrice weekly. Proc. Am. Soc. Clin. Oncol., 17: 211, 1998.